Compare KPTI & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | HQI |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.0M | 153.8M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | HQI |
|---|---|---|
| Price | $9.40 | $10.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $22.17 | $13.00 |
| AVG Volume (30 Days) | ★ 604.4K | 24.6K |
| Earning Date | 02-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 412.84 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $146,067,000.00 | $31,691,000.00 |
| Revenue This Year | $3.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.92 |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $7.38 |
| 52 Week High | $10.38 | $15.75 |
| Indicator | KPTI | HQI |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 49.12 |
| Support Level | $5.90 | $10.28 |
| Resistance Level | $9.94 | $11.20 |
| Average True Range (ATR) | 0.92 | 0.57 |
| MACD | 0.32 | -0.13 |
| Stochastic Oscillator | 87.50 | 26.04 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.